Adam K Zienkiewicz1, Nicolás Verschueren van Rees1, Martin Homer2, Jason J Ong3, Hannah Christensen4, Darryl Hill5, Katharine J Looker4, Paddy Horner4, Gwenda Hughes6, Katy M E Turner7. 1. Department of Engineering Mathematics, University of Bristol, Bristol BS8 1UB, UK; and School of Veterinary Sciences, University of Bristol, Langford House, Langford, Bristol BS40 5DU, UK. 2. Department of Engineering Mathematics, University of Bristol, Bristol BS8 1UB, UK. 3. Clinical Research and Development, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; and Central Clinical School, Monash University, Clayton, Vic. 3800, Australia; and Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. 4. Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. 5. School of Cellular and Molecular Medicine, University of Bristol, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, UK. 6. Instituto de Medicina Tropical, Universidade de São Paulo, Avenuenida Dr Enéas Carvalho de Aguiar, 470, CEP 05403-000, São Paulo, Brasil; and Blood Safety, Hepatitis, STI & HIV Division, National Infection Service, Public Health England, NW9 5EQ, UK. 7. School of Veterinary Sciences, University of Bristol, Langford House, Langford, Bristol BS40 5DU, UK; and Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK; and Corresponding author. Email: katy.turner@bristol.ac.uk.
Abstract
Background Antimicrobial-resistant (AMR) gonorrhoea is a global public health threat. Discriminatory point-of-care tests (POCT) to detect drug sensitivity are under development, enabling individualised resistance-guided therapy. METHODS: An individual-based dynamic transmission model of gonorrhoea infection in MSM living in London has been developed, incorporating ciprofloxacin-sensitive and resistant strains. The time-dependent sexual contact network is captured by periodically restructuring active connections to reflect the transience of contacts. Different strategies to improve treatment selection were explored, including discriminatory POCT and selecting partner treatment based on either the index case or partner susceptibility. Outcomes included population prevalence of gonorrhoea and drug dose counts. RESULTS: It is shown that using POCT to detect ciprofloxacin-sensitive infections could result in a large decrease in ceftriaxone doses (by 70% compared with the reference case in the simulations of this study). It also suggests that ceftriaxone use can be reduced with existing technologies, albeit to a lesser degree; either using index case sensitivity profiles to direct treatment of partners, or testing notified partners with strain discriminatory laboratory tests before treatment, reduced ceftriaxone use in our model (by 27% and 47% respectively). CONCLUSIONS: POCT to detect ciprofloxacin-sensitive gonorrhoea are likely to dramatically reduce reliance on ceftriaxone, but requires the implementation of new technology. In the meantime, the proportion of unnecessary ceftriaxone treatment by testing partners before treatment could be reduced significantly. Alternatively, index case sensitivity profiles could be used to select effective treatments for partners.
Background Antimicrobial-resistant (AMR) gonorrhoea is a global public health threat. Discriminatory point-of-care tests (POCT) to detect drug sensitivity are under development, enabling individualised resistance-guided therapy. METHODS: An individual-based dynamic transmission model of gonorrhoea infection in MSM living in London has been developed, incorporating ciprofloxacin-sensitive and resistant strains. The time-dependent sexual contact network is captured by periodically restructuring active connections to reflect the transience of contacts. Different strategies to improve treatment selection were explored, including discriminatory POCT and selecting partner treatment based on either the index case or partner susceptibility. Outcomes included population prevalence of gonorrhoea and drug dose counts. RESULTS: It is shown that using POCT to detect ciprofloxacin-sensitive infections could result in a large decrease in ceftriaxone doses (by 70% compared with the reference case in the simulations of this study). It also suggests that ceftriaxone use can be reduced with existing technologies, albeit to a lesser degree; either using index case sensitivity profiles to direct treatment of partners, or testing notified partners with strain discriminatory laboratory tests before treatment, reduced ceftriaxone use in our model (by 27% and 47% respectively). CONCLUSIONS: POCT to detect ciprofloxacin-sensitive gonorrhoea are likely to dramatically reduce reliance on ceftriaxone, but requires the implementation of new technology. In the meantime, the proportion of unnecessary ceftriaxone treatment by testing partners before treatment could be reduced significantly. Alternatively, index case sensitivity profiles could be used to select effective treatments for partners.
Authors: Ava Lorenc; Emer Brangan; Joanna M Kesten; Paddy J Horner; Michael Clarke; Megan Crofts; Jonathan Steer; Jonathan Turner; Peter Muir; Jeremy Horwood Journal: BMJ Open Date: 2021-10-22 Impact factor: 3.006
Authors: Reza Yaesoubi; Ted Cohen; Katherine Hsu; Thomas L Gift; Sancta B St Cyr; Joshua A Salomon; Yonatan H Grad Journal: PLoS Comput Biol Date: 2022-02-09 Impact factor: 4.475
Authors: Sandra Montes-Olivas; Yaz Ozten; Martin Homer; Katy Turner; Christopher K Fairley; Jane S Hocking; Desiree Tse; Nicolas Verschueren van Rees; William C W Wong; Jason J Ong Journal: Front Public Health Date: 2022-07-27
Authors: Emma M Harding-Esch; Susie E Huntington; Michael J Harvey; Georgie Weston; Claire E Broad; Elisabeth J Adams; S Tariq Sadiq Journal: Euro Surveill Date: 2020-10